“For us, Technology for Life is more than a mission statement.”
(Stefan Dräger, Executive Board Chairman)
Dräger is a leading international company in the fields of medical and safety technology. Founded in Lübeck in 1889, Dräger has grown into a worldwide, DAX-listed enterprise in its fifth generation as a family-run business. Our long-term success is predicated on a value-oriented corporate culture with four central strengths: close collaboration with our customers, the expertise of our employees, continuous innovation and outstanding quality.
“Technology for Life” is our guiding principle. Wherever they are deployed – in clinical settings, industry, mining or emergency services – Dräger products protect, support and save lives.
The safety division offers its customers complete hazard management solutions with a special focus on personal safety and protecting production facilities. The safety division’s current portfolio includes stationary and mobile gas detection systems, respiratory protection, firefighting equipment, professional diving gear, and alcohol and drug-testing instruments.
The medical division’s product range covers anesthesia workstations, ventilation equipment for intensive care, emergency and mobile ventilation units, warming therapy equipment for infants, patient monitoring equipment, IT solutions and gas management systems.
Dräger has about 13.500 employees worldwide and is present in over 190 countries around the globe. The Group maintains sales and service organizations in over 40 countries. Its development and production facilities are based in Germany, Great Britain, Sweden, South Africa, the USA, Brazil, the Czech Republic and China.
Contact
Dräger South Africa (Pty) Ltd
PO Box 4676, Rivonia, 2128
Tel: +27 11 069 4246
Fax: +27 11 465 6953
Marius Fourie highlights implications of the recent merger between the company’s two subsidiaries and the unparalleled levels of value and service the consolidated organization will offer. He also illustrates the affiliate’s strategies…
Diabetes is surging in Africa. But, in a continent where healthcare systems are set up to support treatments for infectious – not non-communicable – diseases, can pharma companies step up…
Can a medicine be considered “available” if it can’t be trusted? As Africa’s manufacturing base expands and its regulatory systems mature, that question is moving to the centre of the…
African healthcare and pharma are moving from ambition to action. Regular PharmaBoardroom contributor Lenias Hwenda explains how, after years of over-dependence on global supply chains, fragmented regulation, and limited local…
Africa accounts for 19 percent of the world’s population and one-quarter of the global disease burden. However, for a host of reasons – both real and perceptual – the continent…
Writing in the July 2025 edition of DIA’s Global Forum magazine, Alex Juma Ismail of the African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD) and Vicki Gold,…
Building on the recent controversy over Tanzania’s handling of a suspected Marburg virus outbreak, Medicines for Africa’s Lenias Hwenda explores how African nations often face disproportionate consequences for outbreak transparency—penalties…
John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into…
The IFPMA’s Sarah Adam, writing in the July 2024 edition of DIA’s Global Forum magazine, looks back on an insightful discussion on the progress towards an African Medicines Agency at…
Several major scientific breakthroughs in HIV prevention and treatment in the past 40 years have successfully transformed HIV from a near-certain ‘death sentence’ to a manageable chronic disease where many…
In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step…
A leading voice in the global fight against HIV, Professor Linda-Gail Bekker works across both scientific research and activism. As CEO and founder of the Desmond Tutu Health Foundation, Prof…
Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to…
See our Cookie Privacy Policy Here
